Clinical Report: UC Irvine awarded $18 million to lead groundbreaking dementia study
Overview
UC Irvine's UCI MIND has secured an $18 million grant to lead a pivotal study on limbic predominant age-related TDP-43 encephalopathy (LATE). This research aims to establish the first trial-ready cohort for LATE, which affects up to 40% of older adults and currently lacks reliable diagnostic tools.
Background
LATE is a neurodegenerative disease that mimics Alzheimer's disease but is characterized by distinct pathological features. The absence of reliable diagnostic tools for LATE complicates clinical management and research efforts. This study is crucial as it seeks to identify and validate biomarkers for LATE, thereby enhancing diagnostic accuracy and patient care.
Data Highlights
No numerical data available in the article.
Key Findings
UCI MIND received an $18 million grant from the National Institute on Aging.
The study will recruit participants aged 85+ from five federally funded Alzheimer’s Disease Research Centers.
Participants will undergo annual MRIs, blood draws, PET scans, and remote cognitive assessments.
The project aims to establish the first trial-ready cohort for LATE.
Experts in AI, informatics, and recruitment science will contribute to the study.
Clinical Implications
The establishment of a trial-ready cohort for LATE may facilitate future clinical trials and improve diagnostic strategies for older adults. Enhanced understanding of LATE could lead to better patient outcomes and more tailored therapeutic approaches.
Conclusion
This landmark study represents a significant step forward in addressing the challenges posed by LATE, potentially transforming the landscape of dementia research and care.
